Human mutations in the Wnt antagonist Sclerostin (SOST) also cause high bone mass through loss of pathway inhibition (Van Buchem disease OMIM 239100 or Sclerostosis OMIM 269500) [18]. This evidence concerns the gene SOST and hyperostosis corticalis generalisata.